Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Top Ten Searches
p acnes corneal ulcer endopthalmitis kaposi esotropia intraocular uveitis optic neuritis anisocoria retinitisYour Article Summary
See Latest ArticlesCost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration
Graefe's Archive for Clinical and Experimental Ophthalmology, 08/17/09
Hernandez–Pastor LJ et al. – The cost per QALY gained with monthly ranibizumab compared with pegaptanib in the minimally classic/occult neovascular AMD population is just below the €30,000 threshold below which new drugs are sometimes regarded as cost–effective strategies in Spain. In this model, the key variables with greater impact on the cost–effectiveness results were the selected time horizon and the chosen extrapolation method, the source for data on pegaptanib efficacy and the number of ranibizumab injections. When administered on an as–needed basis, ranibizumab was a cost–effective strategy compared to pegaptanib in this population.
Related Articles
Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration
Retina, 11/11/09
Relevance Score: 68%
Statin Use and the Incidence of Advanced Age-Related Macular Degeneration in the Complications of Age-Related Macular Degeneration Prevention Trial
Ophthalmology, 10/28/09
Relevance Score: 68%
siRNA therapeutics for age-related macular degeneration: promises and pitfalls
Expert Review of Ophthalmology, 10/22/09
Relevance Score: 68%
Bevacizumab vs Ranibizumab for Age-related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial
American Journal of Ophthalmology, 10/07/09
Relevance Score: 67%
The pathogenic role of the canonical Wnt pathway in age-related macular degeneration
Investigative Ophthalmology and Visual Science, 11/18/09
Relevance Score: 66%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study
Acta Ophthalmologica, 12/18/09
Pre-Treatment with Intravitreal Triamcinolone Prior to Laser for Diabetic Macular Edema: 6-Month Results of a Randomised, Placebo-Controlled Trial
Investigative Ophthalmology and Visual Science, 12/18/09
Exploratory Analysis of Diabetic Retinopathy Progression Through 3 Years in a Randomized Clinical Trial That Compares Intravitreal Triamcinolone Acetonide With Focal/Grid Photocoagulation
Archives of Ophthalmology, 12/18/09
Today in Retina...keeping you current
Receive free subspecialty "5-minute updates" via email
Pre-Treatment with Intravitreal Triamcinolone Prior to Laser for Diabetic Macular Edema: 6-Month Results of a Randomised, Placebo-Controlled Trial
Investigative Ophthalmology and Visual Science, 12/18/09
Adverse Events After Pars Plana Vitrectomy Among Medicare Beneficiaries
Archives of Ophthalmology, 12/18/09
Melanoma-Associated Retinopathy
Archives of Ophthalmology, 12/18/09
Article Search
Sponsor